Search by Drug Name or NDC
NDC 72855-0102-01 Rivastigmine Transdermal System 13.3 mg/24h Details
Rivastigmine Transdermal System 13.3 mg/24h
Rivastigmine Transdermal System is a TRANSDERMAL PATCH, EXTENDED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Adhexpharma. The primary component is RIVASTIGMINE.
MedlinePlus Drug Summary
Rivastigmine transdermal patches are used to treat dementia (a brain disorder that affects the ability to remember, think clearly, communicate, and perform daily activities and may cause changes in mood and personality) in people with Alzheimer's disease (a brain disease that slowly destroys the memory and the ability to think, learn, communicate and handle daily activities). Transdermal rivastigmine is also used to treat dementia in people with Parkinson's disease (a brain system disease with symptoms of slowing of movement, muscle weakness, shuffling walk, and loss of memory). Rivastigmine is in a class of medications called cholinesterase inhibitors. It improves mental function (such as memory and thinking) by increasing the amount of a certain natural substance in the brain.
Related Packages: 72855-0102-01Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Rivastigmine Transdermal Patch
Product Information
| NDC | 72855-0102 |
|---|---|
| Product ID | 72855-102_087b5a9e-3157-abc7-e063-6394a90a554b |
| Associated GPIs | |
| GCN Sequence Number | n/a |
| GCN Sequence Number Description | n/a |
| HIC3 | n/a |
| HIC3 Description | n/a |
| GCN | n/a |
| HICL Sequence Number | n/a |
| HICL Sequence Number Description | n/a |
| Brand/Generic | n/a |
| Proprietary Name | Rivastigmine Transdermal System |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Rivastigmine |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | PATCH, EXTENDED RELEASE |
| Route | TRANSDERMAL |
| Active Ingredient Strength | 13.3 |
| Active Ingredient Units | mg/24h |
| Substance Name | RIVASTIGMINE |
| Labeler Name | Adhexpharma |
| Pharmaceutical Class | Cholinesterase Inhibitor [EPC], Cholinesterase Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA209063 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 72855-0102-01 (72855010201)
| NDC Package Code | 72855-102-01 |
|---|---|
| Billing NDC | 72855010201 |
| Package | 30 POUCH in 1 CARTON (72855-102-01) / 1 PATCH in 1 POUCH (72855-102-02) / 24 h in 1 PATCH |
| Marketing Start Date | 2019-12-19 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |